Raras
Buscar doenças, sintomas, genes...
Artrite juvenil idiopática
ORPHA:92CID-11 · FA24OMIM 604302DOENÇA RARA

A Artrite Idiopática Juvenil (AIJ) é o nome dado a um grupo de doenças inflamatórias que afetam as articulações, de causa desconhecida, que começam antes dos 16 anos de idade e duram mais de 6 semanas. O termo artrite idiopática juvenil foi escolhido para indicar que não há um mecanismo conhecido que cause a doença e para ressaltar a necessidade de excluir outros tipos de artrite que surgem em condições médicas específicas (em particular, a artrite associada a doenças infecciosas, inflamatórias e hemato-oncológicas).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A Artrite Idiopática Juvenil (AIJ) é o nome dado a um grupo de doenças inflamatórias que afetam as articulações, de causa desconhecida, que começam antes dos 16 anos de idade e duram mais de 6 semanas. O termo artrite idiopática juvenil foi escolhido para indicar que não há um mecanismo conhecido que cause a doença e para ressaltar a necessidade de excluir outros tipos de artrite que surgem em condições médicas específicas (em particular, a artrite associada a doenças infecciosas, inflamatórias e hemato-oncológicas).

Pesquisas ativas
29 ensaios
336 total registrados no ClinicalTrials.gov
Publicações científicas
8.647 artigos
Último publicado: 2026 Apr 16

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
4.7
France
Início
Childhood
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🦴
Ossos e articulações
22 sintomas
❤️
Coração
6 sintomas
📏
Crescimento
6 sintomas
👁️
Olhos
4 sintomas
🫃
Digestivo
4 sintomas
🧬
Pele e cabelo
4 sintomas

+ 48 sintomas em outras categorias

Características mais comuns

Glaucoma
Hepatoesplenomegalia
Regurgitação aórtica
Dor abdominal
Prurido
Osteopenia
103sintomas
Sem dados (103)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 103 características clínicas mais associadas, ordenadas por frequência.

Glaucoma
HepatoesplenomegaliaHepatosplenomegaly
Regurgitação aórticaAortic regurgitation
Dor abdominalAbdominal pain
PruridoPruritus

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico8.647PubMed
Últimos 10 anos200publicações
Pico2026155 papers
Linha do tempo
2026Hoje · 2026🧪 1991Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

11 genes identificados com associação a esta condição.

MIFAnti-Muellerian hormoneCandidate gene tested inTolerante
FUNÇÃO

The anti-Muellerian hormone (AMH) plays an important role in several reproductive functions (PubMed:14742691, PubMed:34155118, PubMed:3754790, PubMed:8469238). Anti-Muellerian hormone binds and activates AMHR2, its specific type-II receptor, that heterodimerizes with type-I receptors (ACVR1 and BMPR1A) to regulate target gene expression through downstream SMAD protein signal transduction (PubMed:20861221, PubMed:34155118). Produced and secreted by Sertoli cells of the male fetus, anti-Muellerian

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (2)
Cell surface interactions at the vascular wallNeutrophil degranulation
MECANISMO DE DOENÇA

Persistent Muellerian duct syndrome 1

A form of male pseudohermaphroditism characterized by a failure of Muellerian duct regression in otherwise normal males.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
29.1 TPM
Cerebelo
21.8 TPM
Cérebro - Hemisfério cerebelar
20.5 TPM
Córtex cerebral
5.6 TPM
Próstata
5.6 TPM
OUTRAS DOENÇAS (3)
systemic-onset juvenile idiopathic arthritiscystic fibrosisjuvenile idiopathic arthritis
HGNC:7097UniProt:P03971
ANKRD55Ankyrin repeat domain-containing protein 55Candidate gene tested inTolerante
LOCALIZAÇÃO

OUTRAS DOENÇAS (2)
rheumatoid factor-negative juvenile idiopathic arthritisoligoarticular juvenile idiopathic arthritis
HGNC:25681UniProt:Q3KP44
PTPN22Tyrosine-protein phosphatase non-receptor type 22Candidate gene tested inTolerante
FUNÇÃO

Acts as a negative regulator of T-cell receptor (TCR) signaling by direct dephosphorylation of the Src family kinases LCK and FYN, ITAMs of the TCRz/CD3 complex, as well as ZAP70, VAV, VCP and other key signaling molecules (PubMed:16461343, PubMed:18056643). Associates with and probably dephosphorylates CBL. Dephosphorylates LCK at its activating 'Tyr-394' residue (PubMed:21719704). Dephosphorylates ZAP70 at its activating 'Tyr-493' residue (PubMed:16461343). Dephosphorylates the immune system a

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (2)
Phosphorylation of CD3 and TCR zeta chainsTranslocation of ZAP-70 to Immunological synapse
MECANISMO DE DOENÇA

Systemic lupus erythematosus

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

EXPRESSÃO TECIDUAL(Tecido-específico)
Linfócitos
50.6 TPM
Baço
13.9 TPM
Sangue
12.7 TPM
Intestino delgado
9.6 TPM
Pulmão
8.7 TPM
OUTRAS DOENÇAS (6)
systemic lupus erythematosusVogt-Koyanagi-Harada diseaseoligoarticular juvenile idiopathic arthritisrheumatoid factor-negative juvenile idiopathic arthritis
HGNC:9652UniProt:Q9Y2R2
LACC1Purine nucleoside phosphorylase LACC1Candidate gene tested inTolerante
FUNÇÃO

Purine nucleoside enzyme that catalyzes the phosphorolysis of adenosine, guanosine and inosine nucleosides, yielding D-ribose 1-phosphate and the respective free bases, adenine, guanine and hypoxanthine (PubMed:31978345). Also catalyzes the phosphorolysis of S-methyl-5'-thioadenosine into adenine and S-methyl-5-thio-alpha-D-ribose 1-phosphate (PubMed:31978345). Also has adenosine deaminase activity (PubMed:31978345). Acts as a regulator of innate immunity in macrophages by modulating the purine

LOCALIZAÇÃO

CytoplasmNucleusEndoplasmic reticulumPeroxisome

MECANISMO DE DOENÇA

Juvenile arthritis

A rare, familial form of juvenile arthritis characterized by autosomal recessive inheritance and onset in early childhood of symmetric, chronic joint inflammation. It causes joint swelling, pain, stiffness and restricted joint movement. JUVAR has high clinical variability. Some patients exhibit systemic symptoms, including quotidian fever, erythematous rash, generalized lymphadenopathy, hepatomegaly, and/or splenomegaly. Others display polyarthritis without systemic inflammation.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
14.4 TPM
Substância negra
12.1 TPM
Testículo
11.5 TPM
Fibroblastos
10.3 TPM
Hipocampo
9.7 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (2)
juvenile arthritis due to defect in LACC1systemic-onset juvenile idiopathic arthritis
HGNC:26789UniProt:Q8IV20
IL6Interleukin-6Candidate gene tested inRestrito
FUNÇÃO

Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism. Binds to IL6R, then the complex associates to the signaling subunit IL6ST/gp130 to trigger the intracellular IL6-signaling pathway (Probable). The interaction with the membrane-bound IL6R and IL6ST stimulates 'classic signaling', whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans-signaling'. Alternatively, 'cluster signaling' occurs when membrane-bound IL6:IL6R complexes on

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (9)
MAPK3 (ERK1) activationMAPK1 (ERK2) activationInterleukin-6 signalingTranscriptional Regulation by VENTXSenescence-Associated Secretory Phenotype (SASP)
MECANISMO DE DOENÇA

Rheumatoid arthritis systemic juvenile

An inflammatory articular disorder with systemic onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.

EXPRESSÃO TECIDUAL(Ubíquo)
Adipose Visceral Omentum
54.4 TPM
Pulmão
29.6 TPM
Fallopian Tube
13.6 TPM
Mama
13.1 TPM
Tecido adiposo
11.8 TPM
OUTRAS DOENÇAS (7)
systemic-onset juvenile idiopathic arthritisinflammatory bowel disease 1Kaposi sarcoma, susceptibility toarteriovenous malformations of the brain
HGNC:6018UniProt:P05231
IL2RAInterleukin-2 receptor subunit alphaCandidate gene tested inTolerante
FUNÇÃO

Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (4)
RAF/MAP kinase cascadeInterleukin receptor SHC signalingInterleukin-2 signalingRUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
MECANISMO DE DOENÇA

Type 1 diabetes mellitus 10

A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.

EXPRESSÃO TECIDUAL(Tecido-específico)
Baço
9.3 TPM
Linfócitos
8.3 TPM
Intestino delgado
7.2 TPM
Adipose Visceral Omentum
3.0 TPM
Pulmão
2.7 TPM
OUTRAS DOENÇAS (4)
immunodeficiency due to CD25 deficiencyrheumatoid factor-negative juvenile idiopathic arthritisoligoarticular juvenile idiopathic arthritistype 1 diabetes mellitus 10
HGNC:6008UniProt:P01589
CD247T-cell surface glycoprotein CD3 zeta chainCandidate gene tested inModerado
FUNÇÃO

Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (9)
Translocation of ZAP-70 to Immunological synapseDownstream TCR signalingPhosphorylation of CD3 and TCR zeta chainsImmunoregulatory interactions between a Lymphoid and a non-Lymphoid cellFCGR3A-mediated phagocytosis
MECANISMO DE DOENÇA

Immunodeficiency 25

An immunological deficiency characterized by T-cells impaired immune response to alloantigens, tetanus toxoid and mitogens.

OUTRAS DOENÇAS (4)
immunodeficiency 25rheumatoid factor-negative juvenile idiopathic arthritisT-B+ severe combined immunodeficiency due to CD3delta/CD3epsilon/CD3zetaoligoarticular juvenile idiopathic arthritis
HGNC:1677UniProt:P20963
STAT4Signal transducer and activator of transcription 4Candidate gene tested inAltamente restrito
FUNÇÃO

Transcriptional regulator mainly expressed in hematopoietic cells that plays a critical role in cellular growth, differentiation and immune response (PubMed:10961885, PubMed:37256972, PubMed:8943379). Plays a key role in the differentiation of T-helper 1 cells and the production of interferon-gamma (PubMed:12213961, PubMed:35614130). Also participates in multiple neutrophil functions including chemotaxis and production of the neutrophil extracellular traps (By similarity). After IL12 binding to

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (5)
Interleukin-20 family signalingInterleukin-21 signalingInterleukin-12 signalingInterleukin-35 SignallingInterleukin-23 signaling
MECANISMO DE DOENÇA

Systemic lupus erythematosus 11

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
34.7 TPM
Pituitária
24.0 TPM
Brain Frontal Cortex BA9
17.3 TPM
Baço
16.7 TPM
Córtex cerebral
15.3 TPM
OUTRAS DOENÇAS (7)
disabling pansclerotic morphea of childhoodpediatric systemic lupus erythematosusoligoarticular juvenile idiopathic arthritissystemic lupus erythematosus
HGNC:11365UniProt:Q14765
HLA-DRB1HLA class II histocompatibility antigen, DRB1 beta chainCandidate gene tested inRestrito
FUNÇÃO

A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells

LOCALIZAÇÃO

Cell membraneEndoplasmic reticulum membraneLysosome membraneLate endosome membraneAutolysosome membrane

VIAS BIOLÓGICAS (7)
Generation of second messenger moleculesTranslocation of ZAP-70 to Immunological synapsePhosphorylation of CD3 and TCR zeta chainsCo-inhibition by PD-1Downstream TCR signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1832.6 TPM
Pulmão
1234.8 TPM
Baço
990.6 TPM
Intestino delgado
607.2 TPM
Nervo tibial
598.3 TPM
OUTRAS DOENÇAS (16)
narcolepsy-cataplexy syndromefollicular lymphomaVogt-Koyanagi-Harada diseasepediatric multiple sclerosis
HGNC:4948UniProt:P01911
PTPN2Tyrosine-protein phosphatase non-receptor type 2Candidate gene tested inAltamente restrito
FUNÇÃO

Non-receptor type tyrosine-specific phosphatase that dephosphorylates receptor protein tyrosine kinases including INSR, EGFR, CSF1R, PDGFR. Also dephosphorylates non-receptor protein tyrosine kinases like JAK1, JAK2, JAK3, Src family kinases, STAT1, STAT3 and STAT6 either in the nucleus or the cytoplasm. Negatively regulates numerous signaling pathways and biological processes like hematopoiesis, inflammatory response, cell proliferation and differentiation, and glucose homeostasis. Plays a mult

LOCALIZAÇÃO

Endoplasmic reticulumEndoplasmic reticulum-Golgi intermediate compartmentNucleusCytoplasmCell membrane

VIAS BIOLÓGICAS (1)
Interleukin-37 signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
26.5 TPM
Ovário
21.1 TPM
Pulmão
20.3 TPM
Fibroblastos
19.6 TPM
Baço
19.0 TPM
OUTRAS DOENÇAS (2)
oligoarticular juvenile idiopathic arthritisrheumatoid factor-negative juvenile idiopathic arthritis
HGNC:9650UniProt:P17706
IL2RBInterleukin-2 receptor subunit betaCandidate gene tested inRestrito
FUNÇÃO

Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15 (PubMed:15123770, PubMed:31040185)

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Interleukin-2 signalingInterleukin-15 signaling
MECANISMO DE DOENÇA

Immunodeficiency 63 with lymphoproliferation and autoimmunity

An autosomal recessive disorder characterized by immune dysregulation resulting in lymphoid proliferation, dermatitis, enteropathy, autoantibodies, hypergammaglobulinemia, and immunodeficiency with recurrent infections. Patients show increased susceptibility to viral infections, particularly cytomegalovirus disease.

EXPRESSÃO TECIDUAL(Tecido-específico)
Linfócitos
132.9 TPM
Baço
45.4 TPM
Sangue
24.8 TPM
Pulmão
10.7 TPM
Intestino delgado
8.6 TPM
OUTRAS DOENÇAS (3)
immunodeficiency 63 with lymphoproliferation and autoimmunityoligoarticular juvenile idiopathic arthritisrheumatoid factor-negative juvenile idiopathic arthritis
HGNC:6009UniProt:P14784

Medicamentos aprovados (FDA)

2 medicamentos encontrados nos registros da FDA americana.

💊 Naproxen (NAPROXEN)
💊 Tofidence (TOCILIZUMAB)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

92 variantes patogênicas registradas no ClinVar.

🧬 MIF: NM_002415.2(MIF):c.-41C>A ()
🧬 MIF: GRCh37/hg19 22q11.21-11.23(chr22:21798907-24636372)x3 ()
🧬 MIF: GRCh37/hg19 22q11.23(chr22:23652549-25002659)x3 ()
🧬 MIF: GRCh37/hg19 22q11.23(chr22:23690388-25066472)x3 ()
🧬 MIF: GRCh37/hg19 22q11.22-11.23(chr22:22989453-25019883)x3 ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 1 variantes classificadas pelo ClinVar.

1
VUS (100.0%)
VARIANTES MAIS SIGNIFICATIVAS
SIAE: NM_170601.5(SIAE):c.1301A>C (p.Lys434Thr) [Uncertain significance]

Vias biológicas (Reactome)

43 vias biológicas associadas aos genes desta condição.

Signaling by BMP Transcriptional regulation of testis differentiation Phosphorylation of CD3 and TCR zeta chains Translocation of ZAP-70 to Immunological synapse Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation Senescence-Associated Secretory Phenotype (SASP) Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling Transcriptional Regulation by VENTX Post-translational protein phosphorylation ADORA2B mediated anti-inflammatory cytokines production CD163 mediating an anti-inflammatory response RAF/MAP kinase cascade RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) Interleukin-2 signaling Interleukin receptor SHC signaling Nef and signal transduction Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Downstream TCR signaling Generation of second messenger molecules FCGR activation Regulation of actin dynamics for phagocytic cup formation Role of phospholipids in phagocytosis Co-inhibition by PD-1 FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis Interleukin-20 family signaling Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation Interleukin-35 Signalling Interleukin-12 signaling Interleukin-23 signaling Interleukin-21 signaling Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) MHC class II antigen presentation Interferon gamma signaling Negative regulation of MET activity Regulation of IFNG signaling Interleukin-37 signaling PKR-mediated signaling Interleukin-15 signaling

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado1
3Fase 36
2Fase 23
1Fase 11
·Pré-clínico9
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Artrite juvenil idiopática

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

20 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT06654882 · Trial of Sequential Medications AfteR TNFi Failure in Juveni…Recrutando
PHASE3
NCT07087912 · Safety and Immunogenicity of the Live Attenuated Tetravalent…Recrutando
PHASE4
NCT06869551 · A Study to Evaluate the Drug Levels, Efficacy, and Safety of…Recrutando
PHASE3
NCT03510442 · Natural History, Genetics, and Pathophysiology of Systemic J…Recrutando
NCT02991469 · A Repeated Dose-finding Study of Sarilumab in Children and A…Recrutando
PHASE2
NCT07517575 · Pharmacokinetics, Efficacy and Safety of Olokizumab In Patie…Recrutando
PHASE2
NCT04833465 · Development of a Therapeutic Endpoint in Pediatric Rheumatol…Recrutando
NCT05754710 · Korea Xeljanz Post-marketing Surveillance for Juvenile Idiop…Recrutando
NCT07243782 · Regulatory Post-Marketing Surveillance in Hidradenitis Suppu…Recrutando
NCT06668181 · An Open-label Study to Evaluate the Pharmacokinetics and Saf…Recrutando
PHASE3
NCT04088396 · A Study of Baricitinib (LY3009104) in Participants From 1 Ye…Recrutando
PHASE3
NCT03773965 · A Study of Baricitinib in Participants From 1 Year to Less T…Recrutando
PHASE3
NCT05609630 · Study of Oral Upadacitinib and Subcutaneous/Intravenous Toci…Recrutando
PHASE3
NCT04806620 · Unhide® Project: A Digital Health Platform to Collect Lifest…Recrutando
NCT06838143 · Ilaris NIS in KoreaRecrutando
NCT06474546 · Feasibility of a Diet Intervention for Juvenile ArthritisRecrutando
NA
NCT01962415 · Reduced Intensity Conditioning for Non-Malignant Disorders U…Recrutando
PHASE2
NCT06222034 · Study to Measure Filgotinib in the Blood of Children and Tee…Recrutando
PHASE1
NCT06870045 · Dynamic Gait Index as a Functional Gait Assessment Measure i…Recrutando
NCT07234747 · Structured vs. Exergaming-Based Core Stabilization in Childr…Recrutando
NA

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
5.529 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 5.529

#1

Clinical predictors of relapse and severe disease phenotype in children with non-systemic juvenile idiopathic arthritis.

European journal of pediatrics2026 Mar 24

The aim of this study was to identify the predictors of relapse and severe disease in non-systemic juvenile idiopathic arthritis (JIA), a heterogeneous childhood disease. Patients with JIA were grouped based on relapse status, and those with ≥ 2 relapses requiring biologics were classified as severe disease phenotype. A total of 142 patients (63.4% female) were included in the study. Seventy-three patients (51.4%) experienced at least one relapse after achieving remission, who were significantly characterized by female gender, younger age at diagnosis, positive ANA test, and longer disease duration. Ankle, elbow, metacarpophalangeal (MCP), and temporomandibular joint (TMJ) involvement was more prevalent in patients who had experienced at least one relapse. Longer disease duration, higher number of joints involved at the time of diagnosis, and MCP involvement were found as independent risk factors for relapse. Twenty patients (14%) were grouped as having a severe disease phenotype, characterized by a younger age at the time of diagnosis, longer disease duration, and a higher number of joints involved throughout the disease course. Younger age at diagnosis, ankle involvement, and TMJ involvement were found to be independent risk factors for a severe disease phenotype. In our study, longer disease duration, MCP joint involvement, and a higher number of joints involved at the time of diagnosis were found to be associated with relapse in non-systemic JIA patients. On the other hand, younger age at diagnosis, ankle and TMJ involvement were associated with severe disease phenotype. • JIA is a chronic joint disease characterized by relapses and remissions, and approximately half of patients experience at least one relapse after remission. • Multiple relapses and bDMARD requirement may define a severe disease course. Younger age, ankle, and TMJ involvement may predict severe disease course. • Relapses may occur with longer disease duration; not every relapse implies a severe disease course.

#2

Effects of active action observation on cognitive, emotional, motor, and somatosensory outcomes in adolescents with juvenile idiopathic arthritis: a prospective exploratory case series.

Frontiers in human neuroscience2026

Juvenile Idiopathic Arthritis (JIA) is a heterogeneous pediatric rheumatic disease characterized by persistent pain, functional limitations, and psychosocial difficulties that frequently persist despite optimized pharmacological treatment. Active Action Observation (AAO), which involves observing and then executing goal-directed movements, has been shown to engage mirror-neuron and visuomotor networks. This approach has shown promise in neurological and orthopedic rehabilitation, but has not been studied in adolescents with JIA. To assess the feasibility, acceptability, and preliminary clinical effects of an eight-week home-based AAO telerehabilitation program in adolescents with JIA. A prospective exploratory case series included 10 adolescents with JIA (11-17 years). The participants completed an eight-week AAO protocol delivered via weekly pre-recorded YouTube videos and brief online follow-up sessions. Outcomes were assessed at baseline, week 4, and week 8 and included pain interference (PROMIS), stress (SSI-SM), self-efficacy (GSES), fear of pain (FOPQ-III), Timed Up and Go (TUG), hand-grip strength, 6-min walk test (6MWT), and cervical pressure pain thresholds (PPT). The analyses focused on descriptive statistics, change scores, percentage change, and robust estimators (Hodges-Lehmann, Kendall's W). AAO was feasible and well accepted, with no participants withdrawing, and only mild and transient adverse effects reported. From baseline to week 8, the median changes were -42.1% for pain interference, -22.2% for stress, +18.8% for self-efficacy, and -25.7% for fear of pain/movement. While functional mobility (TUG) showed improvement, handgrip strength and 6-min walk test responses were found to be heterogeneous, and cervical PPT exhibited a pattern of increased sensitivity. In line with AAO's neurocognitive framework, the observed reduction in fear of pain, coupled with increased self-efficacy and reduced stress, may indicate an update in threat-related motor representations. This update disrupts the previously formed "movement = danger" association, thereby enabling safer functional engagement and less pain interference. AAO delivered at home via telerehabilitation appears to be a feasible, acceptable, and potentially beneficial adjunct for adolescents with JIA, particularly for pain-related and psychological outcomes. These preliminary findings support the feasibility of AAO and justify future controlled trials to establish its efficacy and elucidate the underlying mechanisms.

#3

Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab.

The Lancet. Rheumatology2026 Mar 02

Juvenile psoriatic arthritis and enthesitis-related arthritis are two categories of juvenile idiopathic arthritis (JIA). Despite available treatments including non-steroidal anti-inflammatory drugs, glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs (DMARDs), and biological DMARDs, a substantial proportion of people do not adequately respond to treatment or do not have long-lasting clinical remission. The aim of this trial was to show the efficacy and safety of ixekizumab in children with active enthesitis-related arthritis and juvenile psoriatic arthritis. COSPIRIT-JIA is an ongoing multicentre, open-label, phase 3 study of ixekizumab, with a randomised adalimumab reference group, in children with a diagnosis of enthesitis-related arthritis (aged 6 to <18 years) and juvenile psoriatic arthritis (aged 2 to <18 years). Eligible participants had three or more active peripheral joints (presence of swelling or limited motion with pain or tenderness) and a bodyweight of at least 10 kg. Participants received subcutaneous administration of either ixekizumab or adalimumab using a weight-based dosing regimen (ixekizumab 40-160 mg starting dose then 20-80 mg once every 4 weeks; and adalimumab 20-40 mg once every 2 weeks). The primary endpoint was the percentage of ixekizumab-treated participants meeting the JIA-American College of Rheumatology (ACR) 30 (defined as at least 30% improvement from baseline in three of any six core outcome variables, with no more than one of the other variables worsening by more than 30%) response criteria at week 16. A Bayesian analysis was used to assess JIA-ACR30 response rate at week 16. Safety data were summarised using descriptive statistics for all participants who received at least one dose of either treatment. People with lived experience of JIA were not involved in the design or conduct of this study. The trial was registered with ClinicalTrials.gov, NCT04527380. The study enrolled 101 patients (ixekizumab n=81, adalimumab n=20) between April 13, 2021, and April 2, 2024, of whom the initial 40 participants naive to biological DMARD treatment were randomly assigned 1:1 to ixekizumab or adalimumab and the additional 61 participants were assigned to ixekizumab. Of the 81 participants who received ixekizumab, 60 were biological DMARD naive (40 with enthesitis-related arthritis and 20 with juvenile psoriatic arthritis) and 21 were biological DMARD experienced (14 with enthesitis-related arthritis and seven with juvenile psoriatic arthritis). The median age of the participants in the ixekizumab group was 14 years (12·0-15·0), of whom 36 (44%) of 81 were female, and 69 (85%) of 81 were White. At week 16, 90% (54 of 60; 95% CI 82·4-97·6) of biological DMARD-naive participants and 86% (18 of 21; 70·7-100·0) of biological DMARD-experienced participants receiving ixekizumab had a JIA-ACR30 response. Treatment-emergent adverse events were mostly mild (46%) or moderate (36%) for the ixekizumab group, with no severe treatment-emergent adverse events reported. The safety profile was consistent with adult psoriatic arthritis or spondyloarthritis and paediatric psoriasis indications. Ixekizumab was well tolerated and effective for the treatment of children with enthesitis-related arthritis and juvenile psoriatic arthritis who are candidates for biological DMARD therapy. Eli Lilly and Company.

#4

Metabolic masqueraders of paediatric and adult rheumatic diseases.

Nature reviews. Rheumatology2026 Feb 25

Inborn errors of metabolism comprise a clinically diverse group of conditions that arise from the decreased activity of an enzyme or metabolite transporter and subsequent blockade in a metabolic pathway. These disorders are typically considered in the differential diagnosis of critically ill neonates or young children presenting with hypoglycaemia, metabolic acidosis or hyperammonaemia. However, beyond these classic presentations, a broader group of inborn errors of metabolism can manifest more subtly, with progressive articular and multi-systemic involvement that mimics or overlaps with typical features of rheumatological disease. Consequently, these conditions might be misdiagnosed for years as rheumatological diseases, including juvenile idiopathic arthritis, systemic sclerosis, idiopathic inflammatory myopathies and systemic lupus erythematosus. Moreover, these disorders provide unique opportunities to understand the complex interplay between metabolism and immune function. With the growing availability of disease-modifying therapies for inborn errors of metabolism, rheumatologists must be able to recognize these disorders, particularly in patients with atypical features or treatment-refractory disease.

#5

Prioritising conditions resulting in chronic lower limb musculoskeletal pain in children and adolescents for development of clinical practice guidelines: an Australian Delphi study.

BMC pediatrics2026 Feb 23

Children and adolescents with chronic lower limb pain may experience delayed diagnosis, misdiagnosis, insufficient or inappropriate treatment initiation or type. Developing condition-specific clinical practice guidelines is one approach to address these healthcare challenges. This research aimed to prioritise the top 10 conditions resulting in chronic lower limb musculoskeletal pain in children that would benefit from the development of Australian clinical practice guidelines. We conducted a modified three round eDelphi. Three multidisciplinary panels were provided a summary of current available evidence and any clinical practice guidelines currently available for 124 conditions identified as resulting in chronic lower limb pain. Panels rated their agreement on the need for the development of clinical practice guidelines and ranked the top 10 conditions. In the final round, parents of children with chronic lower limb musculoskeletal pain rated the appropriateness of the top 10 conditions for guideline development. Forty-four Australian health care professionals (22 allied health, 7 paediatric medical specialists, and 13 general practitioners) participated in Rounds 1 and 2 with a retention rate of 100%. Sixteen parents participated in the confirmatory round. The top 10 conditions prioritised for clinical practice guideline development were generalised joint hypermobility, growing pains, musculoskeletal pain, Juvenile Idiopathic Arthritis, joint instability, avascular necrosis, Legg-Calve-Perthes, flat foot, slipped capital femoral epiphysis and patellofemoral pain syndrome. Healthcare professionals prioritised 10 conditions that require development of clinical practice guidelines. Parents of children and adolescents with chronic lower limb pain provided feedback on the appropriateness of the 10 prioritised conditions for guideline development. These guidelines should be multidisciplinary, co-designed with families and relevant to all health settings. The online version contains supplementary material available at 10.1186/s12887-026-06600-4.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC6.221 artigos no totalmostrando 197

2026

Distinguishing acute lymphoblastic leukemia from juvenile idiopathic arthritis in children with musculoskeletal complaints: a retrospective cross-sectional study.

BMC pediatrics
2026

Modeling, Simulation, and Extrapolation to Optimize Pediatric Development Plan: Sarilumab Polyarticular-Course juvenile arthritis Application.

Journal of pharmacokinetics and pharmacodynamics
2026

Performance evaluation of an adalimumab biosimilar autoinjector and its reference device: comparative use human factors study in patients with rheumatoid arthritis and juvenile idiopathic arthritis.

Drug delivery
2026

[Noninfectious uveitis in childhood : Clinical aspects, diagnostics, treatment and transition].

Die Ophthalmologie
2026

Methotrexate Therapy in Juvenile Idiopathic Arthritis: No Clinically Relevant Pulmonary Impairment but Frequent Transient Liver Enzyme Elevations in a Longitudinal Single-Center Pediatric Cohort of 274 Children Over 30 Years.

ACR open rheumatology
2026

The gut-joint axis in juvenile idiopathic arthritis.

Arthritis research &amp; therapy
2026

Clinical predictors of relapse and severe disease phenotype in children with non-systemic juvenile idiopathic arthritis.

European journal of pediatrics
2026

Application of a novel Musculoskeletal Ultrasound Sum Score (MUSS) in the follow-up of patients with juvenile idiopathic arthritis.

Rheumatology (Oxford, England)
2026

A proposal for the implementation of telemedicine in Japan for rheumatoid arthritis, juvenile idiopathic arthritis, and systemic lupus erythematosus: review article.

Modern rheumatology
2026

Morel Lavallée Lesion Following Excessive Physiotherapy for Ankle Arthritis in a Child with Juvenile Idiopathic Arthritis: Correspondence.

Indian journal of pediatrics
2026

Clinical characteristics and quality of life measures in children with glaucoma-suspect or glaucoma diagnoses in chronic, noninfectious uveitis.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
2026

Etiologies of Wrist Arthritis in the Young Patient.

Hand clinics
2026

AA amyloidosis in inflammatory joint diseases in the era of biological therapies: prevalence, manifestations, management and evolution.

Joint bone spine
2026

The Auditory Manifestations of Autoimmune Rheumatologic Diseases: A Review of Current Evidence.

Current rheumatology reviews
2026

Rheumatic diseases in childhood: Clinical and immunological characteristics of a pediatric cohort at a tertiary hospital.

Reumatologia clinica
2026

Single-centre observational study of anti-adalimumab antibody development in children and young people treated for juvenile idiopathic arthritis and/or non-infectious uveitis.

The British journal of ophthalmology
2026

A Narrative Review of Secukinumab in Spondyloarthritis and Psoriatic Arthritis: Treating the Whole Patient.

Rheumatology and therapy
2026

Paradoxical Expression of Ionotropic Glutamate Receptors in Leucocytes.

Clinical reviews in allergy &amp; immunology
2026

Effects of very early arthritis on pain, behavior, and hippocampal TNF/BDNF in rats.

Pediatric research
2026

Long-term comorbidity patterns in juvenile idiopathic arthritis.

Clinical and experimental rheumatology
2026

Overview of elbow arthritis, a rare involvement in patients with juvenile idiopathic arthritis.

Advances in rheumatology (London, England)
2026

Pregnancy outcomes in juvenile idiopathic arthritis: systematic review and meta-analysis.

Proceedings (Baylor University. Medical Center)
2026

Juvenile idiopathic arthritis and pregnancy.

Proceedings (Baylor University. Medical Center)
2026

Effects of active action observation on cognitive, emotional, motor, and somatosensory outcomes in adolescents with juvenile idiopathic arthritis: a prospective exploratory case series.

Frontiers in human neuroscience
2026

Cost-Utility and Budget Impact Analysis of Tumor Necrosis Factor-Alpha Inhibitors for the Treatment of Refractory Nonsystemic Juvenile Idiopathic Arthritis in Thailand.

Value in health regional issues
2026

Clinical characteristics and diagnostic indicators of childhood-onset systemic lupus erythematosus complicated with macrophage activation syndrome.

Clinical rheumatology
2026

Real-world use of biologics for non-systemic juvenile idiopathic arthritis: information from a Japanese hospital claims database.

Modern rheumatology
2026

Highlights on the Contribution of Gut Microbiota to Immune-Mediated Diseases in Childhood.

Mediterranean journal of hematology and infectious diseases
2026

Brachial artery flow-mediated dilation is less repeatable in children with a chronic inflammatory disease compared to their healthy peers.

Clinical physiology and functional imaging
2026

Hematopoietic Stem Cell Transplantation in Rheumatic Diseases.

International journal of rheumatic diseases
2026

Defining Inactivity of Juvenile Spondyloarthropathies: Delphi Study Among Pediatric Rheumatology Academy (PeRA) From Türkiye.

International journal of rheumatic diseases
2026

Association between asthma and juvenile idiopathic arthritis in children in the United States: a propensity score weighted cross-sectional study.

Pediatric rheumatology online journal
2026

Efficacy of combined JAK1/2 inhibition and cyclosporine in paediatric-onset Still's disease with lung involvement: a case report.

Pediatric rheumatology online journal
2026

ACR Appropriateness Criteria® Joint Pain: Idiopathic Arthritis-Child.

Journal of the American College of Radiology : JACR
2026

Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study.

Rheumatology and therapy
2026

2016 sJIA-MAS criteria and a step-up therapeutic approach in KD-MAS: insights from a combined cohort and literature review.

RMD open
2026

High Healthcare Utilization Preceding Diagnosis with Juvenile Idiopathic Arthritis.

Arthritis care &amp; research
2026

Trajectories of Physical Function in Canadian Children with Juvenile Idiopathic Arthritis.

Arthritis care &amp; research
2026

Reliability and Construct Validity of the Physician's Global Assessment of Lung Disease in Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease.

ACR open rheumatology
2026

Soluble factors released from fibroblast-like synoviocytes of JIA patients with future extended course can condition persistent JIA synovial fibroblasts for increased IL-6 production.

Arthritis research &amp; therapy
2026

Incidence and Prevalence of Non-Infectious Uveitis: A Systematic Review and Meta-Analysis.

Retina (Philadelphia, Pa.)
2026

Disease Damage in Juvenile Idiopathic Arthritis: Authors' Reply.

Indian journal of pediatrics
2026

Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab.

The Lancet. Rheumatology
2026

Targeted delivery of curcumin based on nanocarriers: potential therapeutic strategies for noninfectious arthritis.

Inflammopharmacology
2026

An abnormal immune response masquerading as infectious conditions.

SAGE open medical case reports
2026

Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome without Camptodactyly: A Pediatric Case and Review of the Literature.

Klinische Padiatrie
2026

Prevalence and risk factors for acute kidney injury at the diagnosis of juvenile idiopathic arthritis in children and its long-term implications for kidney health.

Pediatric nephrology (Berlin, Germany)
2026

Biologic and targeted synthetic therapies in juvenile idiopathic arthritis: a review of current and emerging therapeutic agents.

Expert opinion on drug safety
2026

Synovial fluid potentiates local fibroblasts to drive monocyte activation in juvenile idiopathic arthritis.

Arthritis research &amp; therapy
2026

Novel advances in juvenile idiopathic arthritis associated uveitis.

Arthritis research &amp; therapy
2026

Characterization of JIA subtypes, clinical features, treatment patterns, and early outcomes in Palestinian children: a retrospective cohort study.

Pediatric rheumatology online journal
2026

[Imaging in hip disorders in childhood and adolescence].

Orthopadie (Heidelberg, Germany)
2026

Drivers of Methotrexate Polyglutamate Concentration in Erythrocytes: Insights from Immune-Mediated Inflammatory Diseases and Pediatric Acute Lymphoblastic Leukemia.

Pharmaceuticals (Basel, Switzerland)
2026

The Effects of Microbiome Modulating Therapies on Inflammatory Markers in Autoimmune Disease: A Systematic Review and Meta-Analysis.

Nutrients
2026

Metabolic and Anthropometric Alterations in Juvenile Idiopathic Arthritis: A Focus on Cardiometabolic Risk and Non-Invasive Evaluation Methods.

Metabolites
2026

Metabolic masqueraders of paediatric and adult rheumatic diseases.

Nature reviews. Rheumatology
2026

Challenges in functional validation and mechanistic interpretation of a novel LACC1 variant in familial juvenile arthritis.

Human genomics
2026

The impact of time to diagnosis on health service use, cost, and quality of life for patients with juvenile idiopathic arthritis: a cost-utility analysis.

Pediatric rheumatology online journal
2026

Inosine-Triphosphate-Pyrophosphatase Activity as a Potential Predictor of Methotrexate Remission in Juvenile Idiopathic Arthritis.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2026

Transition of serum-free IL-18 levels in systemic juvenile idiopathic arthritis measured by a novel detection method.

Cytokine
2026

Prioritising conditions resulting in chronic lower limb musculoskeletal pain in children and adolescents for development of clinical practice guidelines: an Australian Delphi study.

BMC pediatrics
2026

A multifaceted interplay between hemophagocytosis, IL-18 and type I IFN distinguishes Still disease from other autoinflammatory diseases.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2026

Pan American League of Associations for Rheumatology: Recommendations for the Treatment of Oligoarticular Juvenile Idiopathic Arthritis.

Journal of clinical rheumatology : practical reports on rheumatic &amp; musculoskeletal diseases
2026

Case Report: A case of autoinflammatory disease with a novel NLRP12 variant-clinical presentation and successful treatment with baricitinib.

Frontiers in medicine
2025

Drug-induced liver injury secondary to anakinra in a patient with systemic juvenile idiopathic arthritis-Case report and literature overview.

Canadian liver journal
2026

Biologic treatment patterns and challenges in defining difficult-to-treat disease in children with polyarticular juvenile idiopathic arthritis: a real-world study.

Expert opinion on biological therapy
2026

Development and validation of a multi-institutional electronic juvenile idiopathic arthritis phenotype.

Seminars in arthritis and rheumatism
2026

Disease Damage in Juvenile Idiopathic Arthritis: Correspondence.

Indian journal of pediatrics
2025

Adherence to Disease Modifying Anti Rheumatic Drugs in Tunisian patients with Juvenile Idiopathic Arthritis: An Observational study.

La Tunisie medicale
2026

Discordance between non-zero physician's global scores and absence of active joints in juvenile idiopathic arthritis: multicenter vs. single-center cohorts.

Frontiers in pediatrics
2026

Symptoms and correlates of depression and anxiety in children and adolescents with juvenile idiopathic arthritis.

Orphanet journal of rare diseases
2026

Interferon-Driven Tryptophan Metabolism Links Inflammation and Mental Health in Juvenile Dermatomyositis.

Inflammation
2026

Mechanobiologic modulation of TMJ loading in juvenile idiopathic arthritis.

Cranio : the journal of craniomandibular practice
2026

Moving towards optimized treatment for children and adolescents with juvenile idiopathic arthritis in sustained remission randomized to continue stable treatment, methotrexate withdrawal or tumor necrosis factor inhibitor withdrawal: study protocol for the Norwegian multi-center MOVE-JIA trial.

Trials
2026

Clinical characteristics of temporomandibular joint involvement in children with juvenile idiopathic arthritis.

European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry
2026

An etiopathogenesis of juvenile idiopathic arthritis: the protein-homeostasis-system hypothesis.

Frontiers in pediatrics
2026

Osteopathia striata with cranial sclerosis, associated with juvenile idiopathic arthritis: A case report and review of literature.

World journal of orthopedics
2026

Rapidly progressive fibrinopurulent pleural empyema with systemic juvenile idiopathic arthritis during treatment with tocilizumab.

Rheumatology advances in practice
2026

Autoantibody signatures in children with celiac disease, juvenile idiopathic arthritis, and polyautoimmunity.

JPGN reports
2026

Morel Lavallée Lesion Following Excessive Physiotherapy for Ankle Arthritis in a Child with Juvenile Idiopathic Arthritis.

Indian journal of pediatrics
2026

Temporomandibular joint manifestation of autoimmune diseases.

The Saudi dental journal
2026

Combination of Methotrexate and Mycophenolate mofetil for Refractory Uveitis & Scleritis: A Case Series.

Retinal cases &amp; brief reports
2026

Whole-body magnetic resonance imaging in rheumatology: advancements, key applications and future perspectives.

La Radiologia medica
2026

Model-Informed Abatacept Dose Recommendation in Pediatric Patients With Acute Graft Versus Host Disease.

Journal of clinical pharmacology
2026

Hip Joint Synovial Cavity Thickness in Early Juvenile Idiopathic Arthritis Without Effusion: A Cross-Sectional Ultrasound Study.

Journal of clinical medicine
2026

From Juvenile Idiopathic Arthritis to Pachydermoperiostosis: A Journey to an Unexpected Rare Diagnosis.

Journal of clinical medicine
2026

Serum bile salt-stimulated lipase levels associates with systemic inflammation and declines with effect of treatment in juvenile idiopathic arthritis.

Pediatric rheumatology online journal
2026

Imaging TMJ in juvenile idiopathic arthritis: beyond accuracy toward clinical impact.

Oral surgery, oral medicine, oral pathology and oral radiology
2026

Impact of the 2018 Japan Floods on Methotrexate and Antirheumatic Drug Prescriptions: A Longitudinal Analysis of the Japanese National Database.

JMA journal
2026

Decoding pulmonary risk in childhood-onset still's disease: immunogenetic determinants and implications for risk stratification.

Respiratory research
2025

Superb microvascular imaging ultrasound of the knee in patients with juvenile idiopathic arthritis-a repeatability study.

Frontiers in pediatrics
2026

Treatment of a Large Cohort of Childhood Chronic Noninfectious Uveitis in a Multicentric Large Study: Adalimumab Versus Methotrexate as First-Line Therapy.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2026

Atypical Early Presentation of Multicentric Carpotarsal Osteolysis: Ankle Pain and Cavovarus Deformity Without Osteolysis.

Cureus
2026

Inflammatory ankle MRI findings in pediatric and young adult patients with familial Mediterranean fever: a comparison with juvenile idiopathic arthritis and chronic nonbacterial osteomyelitis.

Skeletal radiology
2026

Clinically validated assay for rapid determination of type I and type II interferon activity in systemic inflammatory diseases.

The Journal of allergy and clinical immunology
2026

Changing paediatric uveitis patterns in Italy: an eight-year experience from the Reggio Emilia Uveitis clinic.

International ophthalmology
2026

Altered B cell activation contributes to the immunopathogenesis of childhood arthritis-associated uveitis.

Nature communications
2026

Causal relationship between body mass index and risk of juvenile idiopathic arthritis: A 2-sample Mendelian randomization study.

Medicine
2026

Juvenile Idiopathic Arthritis Registry at King Abdullah Specialized Children's Hospital (JIAR-KASCH) in Riyadh, Saudi Arabia.

Saudi medical journal
2026

Still's Disease and Autoinflammation: Positioning an Inflammatory Syndrome on the Autoinflammation-Autoimmunity Spectrum.

Current rheumatology reports
2026

From Misdiagnosis to Genetic Confirmation: A Brazilian Familial Report of Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome-A Case-Based Review.

Case reports in pediatrics
2025

Deep learning and radiomics-based system for early diagnosis of hip synovitis in juvenile idiopathic arthritis.

Frontiers in immunology
2025

PRO-KIND consensus protocol for classification, monitoring, and therapy in pediatric rheumatology: persistent oligoarticular juvenile idiopathic arthritis.

Frontiers in pediatrics
2026

Non-systemic Juvenile Idiopathic Arthritis: How do the provisional PRINTO criteria shape the classification?

The Journal of rheumatology
2026

Understanding the Current Landscape of Health Disparities Research Among Youth With Juvenile Idiopathic Arthritis.

The Journal of rheumatology
2026

A 15-Year-Old Patient With History of Juvenile Idiopathic Arthritis Presenting With a Painful Skin Rash.

Pediatrics in review
2026

Reassessing the prevalence of monophasic, polyphasic and persistent disease courses in still's disease.

Seminars in arthritis and rheumatism
2026

Safety and Effectiveness of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan: A Post-Marketing Surveillance Study.

Rheumatology and therapy
2025

Dietary and complementary oral supplements for the management of chronic diseases in children: a systematic review.

Frontiers in pediatrics
2025

Global burden and genetic insights of RA and JIA in ages 0-19 years: GBD 2021 and MR analysis.

Frontiers in immunology
2026

Characterization of TNF-Alpha Inhibitor Induced Paradoxical Psoriasiform Dermatitis at a Single Center via Retrospective Chart Review.

Pediatric dermatology
2025

Comparative risk of systemic autoimmune diseases in juvenile idiopathic arthritis treated with TNF-α or IL-6 inhibitors: a real-world cohort study.

Frontiers in immunology
2025

Advancing Precision Medicine in Adult-Onset Still's Disease: Insights into Biomarkers, Therapies, and COVID-19 Impacts.

Mediterranean journal of rheumatology
2026

Toward Personalized Withdrawal of TNF-α Inhibitors in Non-Systemic Juvenile Idiopathic Arthritis: Predictors of Biologic-Free Remission and Flare.

Pharmaceuticals (Basel, Switzerland)
2025

Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period.

Pharmaceuticals (Basel, Switzerland)
2026

Systemic Immunomodulatory Therapy, Anterior Chamber Inflammation, and the Use of Topical Corticosteroids in Juvenile Idiopathic Arthritis-Associated Uveitis: A Long-Term Real-Life Observational Study.

Journal of clinical medicine
2026

Early-Life Gut Microbiota: Education of the Immune System and Links to Autoimmune Diseases.

Microorganisms
2026

Gait Characteristics in Children with Juvenile Idiopathic Arthritis and Secondary Scoliosis.

Children (Basel, Switzerland)
2026

The Impact of Vitreoretinal Surgery in Patients with Uveitis: Current Strategies and Emerging Perspectives.

Diagnostics (Basel, Switzerland)
2025

Physical activity in children aged 7-13 years with juvenile idiopathic arthritis. Is it significantly altered? A case-control study.

Reumatologia
2025

From arthritis to central sensitization: targeting the neuro-immune axis via microglial modulation in acupuncture treatment for Juvenile Idiopathic Arthritis-associated pain.

Frontiers in immunology
2026

Muscle mass, strength, and sarcopenia in juvenile idiopathic arthritis: a scoping review.

Pediatric rheumatology online journal
2026

TeMPRA: advancing continuing professional development in pediatric rheumatology in Japan.

Pediatric rheumatology online journal
2026

Temporomandibular disorder in children with juvenile idiopathic arthritis with and without temporomandibular joint involvement compared to controls - a two-year prospective multicenter cohort study.

BMC oral health
2026

Identification of potential diagnostic biomarkers for systemic juvenile idiopathic arthritis by integrative transcriptomic analysis.

Autoimmunity
2026

Juvenile rhupus syndrome: A case report of coexistence of JIA and SLE.

Medicine
2026

Evaluation of adalimumab tapering regimens in children and adolescents with juvenile idiopathic arthritis in remission: a simulation study.

Pediatric rheumatology online journal
2026

Effectiveness of Biological Treatment on Hip Involvement in Inflammatory Rheumatic Diseases.

Current rheumatology reviews
2026

Ultrasound to Assess the Temporomandibular Joint of Children With Juvenile Idiopathic Arthritis: A Systematic Review.

International journal of dentistry
2026

Toward Optimal Treatment Outcomes in New-Onset Polyarticular-Course Juvenile Idiopathic Arthritis.

Paediatric drugs
2025

The association between Children's sleep quality and juvenile idiopathic arthritis.

Frontiers in pediatrics
2026

Renal involvement in different subtypes of children with juvenile idiopathic arthritis: results from a single-center cohort.

Clinical rheumatology
2026

Effect of exercise interventions on physical function, cardiorespiratory fitness, and health-related quality of life in patients with juvenile idiopathic arthritis: a meta-analysis of randomized controlled trials.

BMC pediatrics
2026

Mental health needs of children and young people with arthritis.

Arthritis research &amp; therapy
2026

Aortic Valve Regurgitation in a Girl With Juvenile Idiopathic Arthritis.

JACC. Case reports
2026

A retrospective study of pediatric rheumatology referrals reveals large discrepancies in referring providers' musculoskeletal exams.

Pediatric rheumatology online journal
2026

NMR-based metabolomics reveals distinct metabolic profiles in juvenile systemic lupus erythematosus and juvenile idiopathic arthritis.

Clinica chimica acta; international journal of clinical chemistry
2026

Serum Calprotectin - What is the Scope of Clinical Application?

Clinical laboratory
2026

Sex Differences in PROMIS Pediatric Depressive Symptoms, Anxiety, and Psychological Stress Among Children and Adolescents Living With Pediatric Rheumatic Diseases.

The Journal of rheumatology
2026

Trials augmented by external control data using balancing weights: A comparison of estimands and estimators.

Contemporary clinical trials
2026

Use of biologic drugs in juvenile idiopathic arthritis patients followed in an adult rheumatology clinic: real-life data from the HUR-BIO biologic registry.

Clinical rheumatology
2026

Ten-Year Registry Analysis of Ocular Inflammation in Taiwan: Distinct Clinical Patterns and Systemic Associations in Adults and Children.

Ocular immunology and inflammation
2026

Exploring the Association Between Autoimmune and Inflammatory Diseases and Uveitis.

American journal of ophthalmology
2026

Tocilizumab-induced psoriatic dermatitis in polyarticular juvenile idiopathic arthritis: A rare case report.

SAGE open medical case reports
2026

Evaluating the osteoclastogenic potential of peripheral blood mononuclear cells in children with chronic nonbacterial osteomyelitis.

JBMR plus
2026

Systemic Onset Juvenile Idiopathic Arthritis in Sickle Cell Anaemia: A Diagnostic Odyssey.

Indian journal of hematology &amp; blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
2026

Impaired Generation of High-Affinity Memory B Cells and Neutralizing Antibodies Against SARS-CoV-2 in Adolescents and Young Adults With Juvenile Idiopathic Arthritis Treated With Tumor Necrosis Factor Inhibitors.

ACR open rheumatology
2025

Transformation of juvenile idiopathic arthritis in adult-oriented rheumatology care.

Turkish journal of medical sciences
2026

Dry synovitis, RF-negative: a rare entity distinct from juvenile idiopathic arthritis.

Rheumatology advances in practice
2026

Development of a scoring system to assist clinicians in the early referral of patients with suspected juvenile idiopathic arthritis: the EasyJIA score.

Arthritis research &amp; therapy
2026

The ADJUST trial and its implications for biologic discontinuation in juvenile idiopathic arthritis-associated uveitis.

Eye (London, England)
2025

Parent and Physician Global Assessment Discordance in Juvenile Arthritis: The Role of Pain Coping Strategies.

Journal of pediatrics. Clinical practice
2025

Mapping the Global Landscape of Temporomandibular Disorders Research in Children and Adolescents From 2000 to 2024: A Bibliometric Analysis.

Pain research &amp; management
2026

PAFLAR guidelines for oligoarticular juvenile idiopathic arthritis.

Clinical rheumatology
2026

Novel hematological indices SII and NLR: Aiding diagnosis, differentiating subtypes, and reflecting disease activity in juvenile idiopathic arthritis.

Journal of orthopaedics
2025

Prevalence and clinical risk factors for methotrexate intolerance in patients with juvenile idiopathic arthritis.

ARP rheumatology
2025

Rescue Therapy With Continuous Intravenous Anakinra Infusion and Plasma Exchange in Refractory Cytokine Storm of Systemic JIA: A Case Report.

Case reports in pediatrics
2025

The epidemiology and biologics treatment patterns of juvenile idiopathic arthritis in Taiwan- an 8-year follow-up.

Frontiers in immunology
2025

Give weekly adalimumab a chance before discontinuing it: a retrospective clinical and pharmacokinetic analysis in pediatric rheumatology.

Arthritis research &amp; therapy
2025

Sustained hippocampal neuroinflammation and subsequent glutamatergic dysfunction in juvenile idiopathic arthritis: evidence from proton magnetic resonance spectroscopy (1H-MRS).

Arthritis research &amp; therapy
2025

Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice.

Pediatric rheumatology online journal
2025

Circulating Aggrecan, Biglycan, and Decorin as Biomarkers of Osteoarticular Alterations in Juvenile Idiopathic Arthritis-A Preliminary Study.

International journal of molecular sciences
2025

A Canadian Advanced Physiotherapist Practitioner Shared-Care Model in Pediatric Rheumatology Offers Safe and Quality Care in the Management of Juvenile Idiopathic Arthritis-Comparing Key Performance Indicators with the PR-COIN Registry.

Children (Basel, Switzerland)
2025

Regional Gastrointestinal Permeability Patterns in Juvenile Idiopathic Arthritis: A Window into Subclinical Inflammation and Microbiota-Driven Disease Mechanisms.

Children (Basel, Switzerland)
2025

[Predicting and in vitro validating new indications of Ginkgolide B via network-medicine framework].

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
2026

Commentary on "Effects of Hydrotherapy on Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis".

Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association
2026

Pharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS).

Rheumatology and therapy
2026

Closed Loop Computer-based Artificial Intelligence Model "Maverik" to Help Diagnose and Differential Diagnoses of Childhood Onset Chronic Nonbacterial Osteomyelitis: Pilot Study.

Journal of clinical rheumatology : practical reports on rheumatic &amp; musculoskeletal diseases
2025

Functional and Computational Interrogation of the Juvenile Idiopathic Arthritis Risk Loci Identifies Candidate Causal SNPs and Target Genes in CD4+ T cells.

medRxiv : the preprint server for health sciences
2026

Pharmacogenetic hSLCO1B1*14-Guided Dosing of Methotrexate in Transgenic Arthritic Mice Normalizes Exposure and Response.

Clinical and translational science
2025

Not Just Sjögren's: A Rare Life-Threatening Manifestation in a Pediatric Patient.

Cureus
2025

Global research trends in MRI of temporomandibular disorders: a bibliometric study and visualization analysis via CiteSpace.

Journal of oral &amp; facial pain and headache
2026

Diagnostic impact of tocilizumab on papillary thyroid cancer in a patient with systemic juvenile idiopathic arthritis.

Rheumatology (Oxford, England)
2025

Anti-phospholipase A2 Receptor-associated Membranous Nephropathy in an Adolescent Boy with HLA-B27-positive Juvenile Idiopathic Arthritis.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
2025

Nonsteroidal Anti-Inflammatory Drug-Induced Granulomatous Interstitial Nephritis in Juvenile Idiopathic Arthritis: A Rare Entity.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
2025

A comprehensive report of disease complications of juvenile idiopathic arthritis using a prospective cohort study.

Pediatric rheumatology online journal
2025

Clinical predictive factors for septic arthritis of the knee in children: A cohort study.

Science progress
2025

The role of systemic immune-inflammation index in differentiation of juvenile idiopathic arthritis from reactive arthritis among Chinese children.

Frontiers in medicine
2025

Risk factors for macrophage activation syndrome in systemic juvenile idiopathic arthritis: a systematic review and meta-analysis.

Frontiers in pediatrics
2025

Risk of uveitis among children with autoimmune diseases: a nationwide matched-cohort study of 3,643 cases.

Frontiers in immunology
2025

Novel insights into the biology of childhood arthritis- lessons learned from the synovium.

Arthritis research &amp; therapy
2026

Comparing Orofacial Manifestations and Oral Health-Related Quality of Life in Previously Treated Young Adults With Idiopathic Condylar Resorption or Juvenile Arthritis in the Temporomandibular Joint.

Orthodontics &amp; craniofacial research
2026

Hip chondrolysis due to enthesitis-related juvenile idiopathic arthritis treated successfully with adalimumab: A case report.

Modern rheumatology case reports
2025

P19 A rare case of PHOAR2-enteropathy syndrome (PHOAR2E; previously known as pachydermoperiostosis) with a causal variant in the SLCO2A1 gene.

The British journal of dermatology
2026

Gut dysbiosis and inflammation in patients with Juvenile Idiopathic Arthritis-Enthesitis Related Arthritis: impact of HLA-B27 status.

Clinical rheumatology
2025

Compositional patterns of device-measured movement behaviour in juvenile idiopathic arthritis: results from the multicentre ActiMON study.

Arthritis research &amp; therapy
2026

Age-Related Osseous Measures of the Temporomandibular Joint and Mandibular Ramus During Childhood Assessed by Magnetic Resonance Imaging.

Orthodontics &amp; craniofacial research
2026

Multicentric carpo-tarsal osteolysis: the importance of imaging studies, genetic findings and clinical expertise in differential diagnosis and follow-up-a case report.

Skeletal radiology
2025

Disseminated Histoplasmosis Following a Single Dose of Adalimumab in a Child With Juvenile Idiopathic Arthritis: Case Report.

The Pediatric infectious disease journal
2026

Changes in Modern Care for Juvenile Idiopathic Arthritis: How Much Does This Affect Health-Related Quality of Life?

The Journal of rheumatology
2026

Examination of HLA-DRB1*15-linked Candidate Antigens in Still Disease With and Without Lung Disease and Drug-Associated Immune Reactions.

The Journal of rheumatology
2026

Hepatic Manifestations in Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome.

The Journal of rheumatology
2025

Causal effect of type 1 diabetes on juvenile idiopathic arthritis and the mediating role of CD8+ natural killer T cells.

The Journal of clinical endocrinology and metabolism
2025

Pediatric rheumatic diseases and vaccinations: a promising alliance.

Frontiers in pediatrics
2025

Methotrexate use in juvenile idiopathic arthritis and its impact on growth plate development: A prospective observational cohort study.

Bioinformation
2025

Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease Cohort.

Arthritis care &amp; research
2026

[Juvenile idiopathic arthritis-persistent oligoarticular subtype : Consensus-based treatment recommendations as part of the ProKind Rheuma Initiative].

Zeitschrift fur Rheumatologie
Ver todos os 6.221 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Artrite juvenil idiopática.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Artrite juvenil idiopática

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Clinical predictors of relapse and severe disease phenotype in children with non-systemic juvenile idiopathic arthritis.
    European journal of pediatrics· 2026· PMID 41872624mais citado
  2. Effects of active action observation on cognitive, emotional, motor, and somatosensory outcomes in adolescents with juvenile idiopathic arthritis: a prospective exploratory case series.
    Frontiers in human neuroscience· 2026· PMID 41834905mais citado
  3. Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab.
    The Lancet. Rheumatology· 2026· PMID 41785908mais citado
  4. Metabolic masqueraders of paediatric and adult rheumatic diseases.
    Nature reviews. Rheumatology· 2026· PMID 41741762mais citado
  5. Prioritising conditions resulting in chronic lower limb musculoskeletal pain in children and adolescents for development of clinical practice guidelines: an Australian Delphi study.
    BMC pediatrics· 2026· PMID 41731457mais citado
  6. Validation of a semi-quantitative ultrasonography score for knee synovitis in juvenile idiopathic arthritis and its association with clinical findings.
    Adv Rheumatol· 2026· PMID 41992287recente
  7. Investigating the utility of sarcopenia associated SARC-F and MSRA questionnaires in identifying falls and self-reported functional impairment in juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J· 2026· PMID 41981641recente
  8. The Asia-Pacific League of Associations for Rheumatology Consensus Recommendations on the Management of Juvenile Idiopathic Arthritis (JIA): Polyarticular Course JIA, Temporomandibular Joint Arthritis, Imaging, and Non-Pharmacologic Therapies.
    Int J Rheum Dis· 2026· PMID 41974617recente
  9. [Clinical characteristics and outcomes analysis of children with rheumatoid factor-positive polyarticular juvenile idiopathic arthritis].
    Zhejiang Da Xue Xue Bao Yi Xue Ban· 2026· PMID 41974575recente
  10. Turner syndrome as a state of increased autoimmune susceptibility: evidence from rheumatic diseases.
    Z Rheumatol· 2026· PMID 41973124recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:92(Orphanet)
  2. OMIM OMIM:604302(OMIM)
  3. MONDO:0011429(MONDO)
  4. GARD:18677(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)
  8. Q861224(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Artrite juvenil idiopática
Compêndio · Raras BR

Artrite juvenil idiopática

ORPHA:92 · MONDO:0011429
Prevalência
1-5 / 10 000
CID-11
Ensaios
29 ativos
Início
Childhood
Prevalência
4.7 (France)
MedGen
UMLS
C0409667
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades